💉 The March 20, 2026 Semaglutide Patent Cliff: Strategic Analysis of India’s GLP-1 Market Realignment
Post

💉 The March 20, 2026 Semaglutide Patent Cliff: Strategic Analysis of India’s GLP-1 Market Realignment

The landscape of metabolic healthcare and chronic disease management across global markets experienced a historic shift on March 20, 2026. With the official expiration of Novo Nordisk’s key formulation patent in India (IN 262697), market exclusivity for Semaglutide—the active pharmaceutical ingredient behind Ozempic and Wegovy—came to an end. Following favorable interim rulings from the Delhi...

🎨 1930 Pop Culture Icons Are Now Public Domain!
Post

🎨 1930 Pop Culture Icons Are Now Public Domain!

Every January 1, Public Domain Day marks a seismic shift in creative liberty and corporate IP strategy. The 95-year copyright threshold has officially expired for works published in 1930. High-profile pop culture icons—including early iterations of Betty Boop, the Blondie comic strip, Pluto (originally named Rover), and iconic literary sleuths like Nancy Drew, Miss Marple,...

🇮🇳 Major India IP Update: Delhi High Court clears Zydus to sell low-cost Nivolumab biosimilar (Tishtha)! ⚕️⚖️
Post

🇮🇳 Major India IP Update: Delhi High Court clears Zydus to sell low-cost Nivolumab biosimilar (Tishtha)! ⚕️⚖️

In the realm of pharmaceutical intellectual property, the intersection between exclusive patent monopolies and public health access represents one of the most intensely contested legal battlegrounds. In early 2026, a Division Bench of the Delhi High Court delivered a groundbreaking precedent by lifting a preliminary injunction against Zydus Lifesciences, allowing the domestic manufacture and market...